Scarica l'app Stockscreener
53.63
3.18%
-1.76
Dopo l'orario di chiusura:
53.63
Precedente Chiudi:
$55.39
Aprire:
$55.83
Volume 24 ore:
563.52K
Relative Volume:
0.88
Capitalizzazione di mercato:
$2.58B
Reddito:
-
Utile/perdita netta:
$-86.97M
Rapporto P/E:
-22.17
EPS:
-2.4189
Flusso di cassa netto:
$-81.88M
1 W Prestazione:
-14.75%
1M Prestazione:
-21.84%
6M Prestazione:
+85.19%
1 anno Prestazione:
+209.46%
Intervallo 1D:
$52.32
$56.00
Intervallo di 1 settimana:
$52.32
$64.61
Portata 52W:
$12.94
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Nome
Mbx Biosciences Inc
Settore
Industria
Telefono
(317) 989-3100
Indirizzo
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
53.63 | 2.58B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-12-04 | Iniziato | Goldman | Sell |
| 2025-11-04 | Iniziato | TD Cowen | Buy |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-08-15 | Ripresa | Jefferies | Buy |
| 2025-08-05 | Iniziato | Mizuho | Outperform |
| 2025-07-16 | Iniziato | Oppenheimer | Outperform |
| 2025-04-10 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | JP Morgan | Overweight |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Stifel | Buy |
Mostra tutto
Mbx Biosciences Inc Borsa (MBX) Ultime notizie
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE - MarketBeat
MBX Biosciences upgraded to Buy on strong Phase 2 data and promising Phase 3 outlook for hypoparathyroidism drug. - Pluang
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX) - Seeking Alpha
MBX BIOSCIENCES ANNOUNCES APPOINTMENT OF JEFF HELD AS CHIEF LEGAL OFFICER - Moomoo
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences at Morgan Stanley conference: pipeline nears key tests By Investing.com - Investing.com Canada
MBXMBX Biosciences Inc Revenue Breakdown - Finviz
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - Yahoo Finance Singapore
MBX Biosciences to Participate in Upcoming Investor Conferences - marketscreener.com
MBX Biosciences will present in New York and online - Stock Titan
MBX Biosciences, Inc. Announces Appointment of Jeff Held as Chief Legal Officer - marketscreener.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - The Manila Times
MBX Biosciences Share Price Chart (MBX) - Investing.com UK
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Stability Report - vinanet.vn
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - sahmcapital.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com
MBX Biosciences (MBX) Slips 2.7% to $66.76, Holding Above Key Support at $63.42Price Target - careplusvn.com
MBX Biosciences Insiders Added US$1.06m Of Stock To Their Holdings - moomoo.com
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88 - moomoo.com
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - vinanet.vn
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - vinanet.vn
MBX Biosciences Q2 2026 Earnings: EPS of -$0.78 Misses Estimates as Clinical Costs MountRevenue Guidance Update - dars.gov.et
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Q2 2026 Earnings: Wider-than-Expected -$0.78 Loss Highlights Accelerated Pipeline InvestmentRevenue Estimate Trend - vinanet.vn
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBX Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com - Investing.com Australia
MBX Biosciences posts Q2 loss, advances obesity pipeline - Investing.com
Mbx Biosciences Inc Azioni (MBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):